Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

1.460 -0.050 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,412,143
Open 1.510
Bid (Size) 1.460 (6,000)
Ask (Size) 1.590 (1,400)
Prev. Close 1.510
Today's Range 1.420 - 1.520
52wk Range 0.4830 - 3.070
Shares Outstanding 109,755,624
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
From Invivyd
Via GlobeNewswire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill

Performance

YTD
-41.6%
-41.6%
1 Month
-6.4%
-6.4%
3 Month
-30.8%
-30.8%
6 Month
-34.5%
-34.5%
1 Year
+118.4%
+118.4%

More News

Read More
News headline image
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Presentation at the World Vaccine Congress Washington
From Invivyd
Via GlobeNewswire
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
Topics Stocks
News headline image
Invivyd (IVVD) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Inc (NASDAQ:IVVD) Emerges as High-Growth Momentum Leader ↗
Via Chartmill
News headline image
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
From Invivyd
Via GlobeNewswire
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Invivyd, Inc. - Common Stock publicly traded?
Yes, Invivyd, Inc. - Common Stock is publicly traded.
What exchange does Invivyd, Inc. - Common Stock trade on?
Invivyd, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Invivyd, Inc. - Common Stock?
The ticker symbol for Invivyd, Inc. - Common Stock is IVVD on the Nasdaq Stock Market
What is the current price of Invivyd, Inc. - Common Stock?
The current price of Invivyd, Inc. - Common Stock is 1.460
When was Invivyd, Inc. - Common Stock last traded?
The last trade of Invivyd, Inc. - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of Invivyd, Inc. - Common Stock?
The market capitalization of Invivyd, Inc. - Common Stock is 160.24M
How many shares of Invivyd, Inc. - Common Stock are outstanding?
Invivyd, Inc. - Common Stock has 160M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.